- Home
- CUE vs ONCY Comparison
CUE vs ONCY Comparison
Compare CUE & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- ONCY
- Stock Information
- Founded
- CUE 2014
- ONCY 1998
- Country
- CUE United States
- ONCY Canada
- Employees
- CUE N/A
- ONCY N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- ONCY Pharmaceuticals and Biotechnology
- Sector
- CUE Health Care
- ONCY Health Care
- Exchange
- CUE Nasdaq
- ONCY Nasdaq
- Market Cap
- CUE 58.9M
- ONCY 49.1M
- IPO Year
- CUE 2018
- ONCY 1999
- Fundamental
- Price
- CUE $0.65
- ONCY $0.34
- Analyst Decision
- CUE Strong Buy
- ONCY Strong Buy
- Analyst Count
- CUE 3
- ONCY 4
- Target Price
- CUE $3.00
- ONCY $4.33
- AVG Volume (30 Days)
- CUE 163.7K
- ONCY 842.4K
- Earning Date
- CUE 05-12-2025
- ONCY 05-14-2025
- Dividend Yield
- CUE N/A
- ONCY N/A
- EPS Growth
- CUE N/A
- ONCY N/A
- EPS
- CUE N/A
- ONCY N/A
- Revenue
- CUE $7,991,000.00
- ONCY N/A
- Revenue This Year
- CUE N/A
- ONCY N/A
- Revenue Next Year
- CUE $25.99
- ONCY N/A
- P/E Ratio
- CUE N/A
- ONCY N/A
- Revenue Growth
- CUE 13.83
- ONCY N/A
- 52 Week Low
- CUE $0.45
- ONCY $0.33
- 52 Week High
- CUE $1.99
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- CUE 40.82
- ONCY 24.62
- Support Level
- CUE $0.61
- ONCY $0.37
- Resistance Level
- CUE $0.71
- ONCY $0.45
- Average True Range (ATR)
- CUE 0.06
- ONCY 0.04
- MACD
- CUE -0.00
- ONCY -0.01
- Stochastic Oscillator
- CUE 30.70
- ONCY 6.62
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.